R J Straka
Affiliation: University of Minnesota
- High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional studyMary K Wojczynski
Department of Biostatistics, University of Alabama at Birmingham, Brimingham, AL, USA
Lipids Health Dis 10:181. 2011..Analyses were stratified by baseline triglycerides (normal vs. elevated) and gender. The effect of PPL on changes in lipoprotein subclasses was assessed using repeated measures ANOVA...
- Determining initial and follow-up costs of cardiovascular events in a US managed care populationRichard H Chapman
US Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA
BMC Cardiovasc Disord 11:11. 2011..This study aims to determine initial and follow-up costs for cardiovascular (CV) events in US managed care enrollees and to compare to healthcare costs for matched patients without CV events...
- Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care settingRobert J Straka
Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN, USA
Cardiovasc Diabetol 8:53. 2009..We conducted a retrospective claims database analysis to evaluate incremental cardiovascular costs in diabetic versus non-diabetic patients hospitalized for a cardiovascular event...
- Assessment of hypercholesterolemia control in a managed care organizationR J Straka
College of Pharmacy, University of Minnesota, Minneapolis, 55455, USA
Pharmacotherapy 21:818-27. 2001..Finally, the successful merging of medical, laboratory, and pharmacy claims databases provides a benchmark for other institutions...
- Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serumRobert J Straka
University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA
Ther Drug Monit 29:197-202. 2007..This method is suitable for quantification of fenofibric acid for clinical pharmacokinetic studies in patients with dyslipidemia...
- Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjectsRobert J Straka
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455 0353, USA
J Clin Pharmacol 46:802-11. 2006..Environmental, genetic, or phenotypic anomalies that may contribute to this discordance should be considered and evaluated in future studies within this unique population...
- Achieving cholesterol target in a managed care organization (ACTION) trialRobert J Straka
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA
Pharmacotherapy 25:360-71. 2005....
- Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in MinnesotaRobert J Straka
University of Minnesota, Department of Experimental and Clinical Pharmacology, 7 109 Weaver Densford Hall, Minneapolis, MN 55455 0353, USA
Biopharm Drug Dispos 27:299-304. 2006..The predominance of the SA phenotype within Minnesota Hmong is confirmed. Further studies evaluating this unexpected prevalence, its genetic basis and potential clinical relevance to drug toxicity and disease are warranted...
- Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet NetworkMichael Y Tsai
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455 0392, USA
Mol Genet Metab 100:118-22. 2010....
- Effect of influenza vaccine on markers of inflammation and lipid profileMichael Y Tsai
Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, USA
J Lab Clin Med 145:323-7. 2005..Consequently, clinical and epidemiologic interpretation of the biomarkers affected should take into account the possible effects of influenza vaccination...
- Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspectiveRobert J Straka
University of Minnesota, Minneapolis, MN, USA
Curr Med Res Opin 23:1517-29. 2007..The present analysis modeled the clinical and economic consequences of initiating atorvastatin versus generic simvastatin in defined US managed care organization patient populations...
- Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotypeNitin Kaila
Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
J Pharmacokinet Pharmacodyn 34:141-56. 2007..In a population pharmacokinetic analysis of metoprolol, a drug that undergoes polymorphic metabolism, it was possible to correctly identify phenotype status using a mixture model...
- The effect of IL6-174C/G polymorphism on postprandial triglyceride metabolism in the GOLDN studyboxsJian Shen
Nutrition and Genomics Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA
J Lipid Res 49:1839-45. 2008..This phenomenon could be responsible for the observed association of this genetic variant with cardiovascular disease risk...
- The SCARB1 gene is associated with lipid response to dietary and pharmacological interventionsYongjun Liu
Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
J Hum Genet 53:709-17. 2008..In summary, our study suggested that the SCARB1 gene may serve as a useful marker that predicts variation in baseline lipid levels, postprandial lipid response, and response to fenofibrate intervention...
- The genetic architecture of fasting plasma triglyceride response to fenofibrate treatmentJennifer A Smith
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI 48109 2029, USA
Eur J Hum Genet 16:603-13. 2008..These results yield insight into the complex biology of fenofibrate response, which can be used to target fenofibrate therapy to individuals who are most likely to benefit from the drug...
- Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN studyChao Qiang Lai
Nutrition and Genomics Laboratory, JM USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St, Boston, MA 02111, USA
Arterioscler Thromb Vasc Biol 27:1417-25. 2007..Apolipoprotein A5 (APOA5) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy...
- Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN studyJian Shen
Nutrition and Genomics Laboratory, Jean Mayer U S Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111 1524, USA
Diabetes Care 31:910-5. 2008..We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome...
- The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network studyDolores Corella
Nutrition and Genomics Laboratory, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111 1524, USA
Clin Chem 53:1144-52. 2007..Apolipoprotein A-II (APOA2) plays an ambiguous role in lipid metabolism, obesity, and atherosclerosis...